| Program | Indication | Funding | MOA | Preclinical | cmc | Phase 1 | Phase 2 | Phase 3 | Rights | |
|---|---|---|---|---|---|---|---|---|---|---|
| VE202 | Inflammatory Bowel Disease |
|
Preclinical Phase complete
|
cmc Phase complete
|
Phase 1 Phase complete
|
Phase 2 Phase in progress
|
Phase 3 Phase not started
|
|
||
| VE303 | C. difficile |
|
|
Preclinical Phase complete
|
cmc Phase complete
|
Phase 1 Phase complete
|
Phase 2 Phase complete
|
Phase 3 Phase in progress
|
|
|
| VE707 | Gram-negative Infections |
|
|
Preclinical Phase complete
|
cmc Phase in progress
|
Phase 1 Phase not started
|
Phase 2 Phase not started
|
Phase 3 Phase not started
|
|
|
|
MOA: Mechanism of Action; CMC; Chemistry, Manufacturing and Controls |
||||||||||
Colonization 
Immuno - |
||||||||||